Australian scientists have discovered how the immune system can control melanoma, a mechanism which could be used to enhance cancer treatments.
Published today in Nature, Peter Doherty Institute for Infection and Immunity (Doherty Institute) and Telethon Kids Institute researchers investigated the role of a particular immune cell, tissue-resident memory T (TRM) cells, in controlling melanoma.
TRM cells were able to control the tumour in the mice for the life of the animal, which is likely to equate to decades of protection in humans.
University of Melbourne PhD student, Simone Park from the Doherty Institute, created an imaging model to study TRM cells’ and melanoma in a mouse model.
“Using a special microscope, we could see individual melanoma cells sitting in the skin of the mouse, and could watch the T cells move through the skin, find the melanoma cells and control the growth of those cells,” Ms Park explained.
One of the main issues for cancer patients is that there is always a risk that the tumour can come back years later, after surgery or chemotherapy.
Previous research has shown that small numbers of cancer cells persist in the body after treatment and that the immune system probably keeps the cancer cells under control but this study in mice could study the immune system directly. This is work that could never be done in people.
“I was able to see through moving images that these TRM cells are important for maintaining the control of the tumour cells; if you remove the TRM cells you have a break in that control and the cancer can start to grow back again,” Ms Park said.
“If you could make more of these TRM cells through immunotherapies, or enhance the activity of those that are already there in some way, you could boost anti-tumour immunity.”
Senior author on the paper, University of Melbourne Associate Professor Thomas Gebhardt, Laboratory Head at the Doherty Institute, said an increase of TRM cells has already been associated with better outcomes in cancer patients, but the way they work to suppress tumours has remained unknown.
“The principal of cutting-edge immunotherapies currently in clinical practise is that they generate a T-cell response. But if we can hone in on one type of T-cell – the TRM cells specifically, we could have an even bigger impact on stopping cancers from coming back,” Associate Professor Gebhardt said.
“We now have a much better understanding of which T-cells are important in controlling skin cancers and how those cells are working but there is still much more work to do to make these cells work even better,” Associate Professor Gebhardt said.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Skin Cancer: Melanoma, Basal Cell, Squamous Cell Carcinoma on February 19, 2019 at 12:35 pm
As much as we might enjoy spending time in the sun, the fact is it can be damaging to the skin. In fact, in some cases it can lead to skin cancer, the most common form of cancer diagnosed in the ... […]
- Keytruda Approved for the Adjuvant Treatment of Patients With Stage III Melanoma on February 19, 2019 at 12:24 pm
Merck announced that the Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following compl... […]
- Researchers develop new one-two punch against melanoma in mouse model on February 19, 2019 at 9:50 am
Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University School of Medicine report two new forms of an older anti-cancer agent they ... […]
- Pembrolizumab Granted FDA Approval for Adjuvant Treatment of Stage 3 Melanoma on February 19, 2019 at 8:23 am
Officials with the FDA have granted approval to Merck’s pembrolizumab (Keytruda) for the adjuvant treatment of melanoma with involvement of lymph node(s) following complete resection, according to a p... […]
- Dr. Weber on FDA Approval of Pembrolizumab for Stage III Melanoma on February 19, 2019 at 6:24 am
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care in Melanoma, discusses the FDA approval of pembrol... […]
- FDA Approves Adjuvant Pembrolizumab in Stage III Melanoma on February 19, 2019 at 6:13 am
The FDA has approved the PD-1 inhibitor pembrolizumab (Keytruda) for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following complete resection. 1 Th... […]
- FDA approves Keytruda for adjuvant treatment of melanoma on February 19, 2019 at 6:11 am
The FDA approved pembrolizumab for adjuvant treatment of patients who have melanoma with lymph node involvement who underwent complete resection. This is the first U.S. approval for pembrolizumab (Key... […]
- FDA Approves Keytruda for High-Risk, Advanced Melanoma on February 19, 2019 at 4:36 am
The Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) – an immunotherapy agent – for the treatment of patients with resected, high-risk, stage 3 melanoma, according to Merck, the ma... […]
- Smoking may limit the body's ability to fight melanoma on February 18, 2019 at 10:40 pm
NBC - Smoking may also limit the body's ability to fight the most deadly form of skin cancer. That's according to a new British study of over 700 patients with melanoma. It showed smokers were 40 perc... […]
- Closing ERK Pathway: A New Way to Deal Melanoma on February 18, 2019 at 10:14 pm
Though there are various types of skin cancers, such as Basal cell carcinoma, Squamous cell carcinoma, Actinic keratosis, and Squamous cell carcinoma in situ, Melanoma poses a monstrous menace to the ... […]
via Bing News